Skip to main content
HERON THERAPEUTICS, INC. /DE/ logo

HERON THERAPEUTICS, INC. /DE/ — Investor Relations & Filings

Ticker · HRTX ISIN · US4277461020 LEI · 549300DR2I1DOPD2IX53 US Manufacturing
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2025-08-13 Major Shareholding Noti…
Country US United States of America
Listing US HRTX

About HERON THERAPEUTICS, INC. /DE/

https://www.herontx.com/

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing therapies to address unmet medical needs in acute care and oncology. The company utilizes its proprietary drug delivery technologies to create novel, best-in-class treatments. Its product portfolio is designed to improve the lives of patients by providing solutions for significant medical issues, including postoperative pain management, with an aim to reduce opioid reliance, as well as managing postoperative and chemotherapy-induced nausea and vomiting.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-13 English
Director's Dealing 2025
Director's Dealing
2025-08-13 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-08-12 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes details about a Cooperation Agreement affecting the Board of Directors, issuance of Series A Convertible Preferred Stock, and multiple refinancing transactions including amendments to credit facilities and private placements. There are no comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). The document primarily announces material definitive agreements and financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a certification, so it is not RPA or RNS. Confidence is high given the clear focus on financing and capital structure changes.
2025-08-12 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or agreements. The text describes the entry into a material definitive agreement (a Framework Agreement) between Heron Therapeutics and Patheon Austria GmbH & Co KG. It does not contain financial statements or detailed financial analysis but rather announces a significant contractual event. The document length is 4273 characters, which is relatively short and focused on the announcement of the agreement. There is no indication that this is a full financial report, earnings release, or management discussion. Therefore, the document fits the category of a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-08-12 English
10-Q
Interim / Quarterly Report Q2 2025
2025-08-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.